Clinical Trials Logo

MET Activating Mutation clinical trials

View clinical trials related to MET Activating Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04084717 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Start date: December 3, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer. Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.